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Introduction
The use of mycophenolate mofetil (MMF) in children
with Systemic Lupus Erythematosus (SLE) is increasing.
However, the clinical benefit of its monitoring has been
scarcely studied, and little is known about its pharmaco-
kinetics (PK) in this context.
Objectives
To describe mycophenolic acid (MPA) PK, and to explore
the relationships between exposure indices to MPA and
the clinical status in children with SL
Methods
This retrospective study included 36 children with SLE
already treated with a maintenance immunosuppressive
therapy including MMF. Full-PK profiles of MPA were
modelled using an iterative two-stage approach and a
simulation approach was applied for model refitting and
validation. Using this a priori PK information, a Bayesian
estimator was then developed that could allow accurate
determination of MPA PK and exposure using 3 blood
samples. The relationships between MPA through con-
centrations (C0), Area under the Curve (AUC) or AUC/
dose values, and the activity of the disease (expressed
using the consensually recommended Systemic Lupus
Erythematosus Disease Activity Index; SLEDAI) were
explored using Receiver Operating Curve (ROC) and
logistic regression analysis.
Results
The ROC curve analysis showed that AUC ≤ 44 mg*h/L
and AUC/dose< = 0.06 mg*h/L/mg were associated with
the best diagnostic performance (Sensitivity of 78% and
94% and specificity of 94% and 56% respectively). When
introduced in logistic regression model these threshold
were associated with an increased risk of active disease
(AUC/dose < 0.06, OR[95%CI] = 59.5 [5.9-588.2],
p = 0.0005; AUC < 44 mg.h/L, OR = 21.2 [2.3-196.1].
Conclusion
AUC> 45 mg * h/L or AUC/dose> 0.06 could be proposed
as a target AUC to limit relapse of the disease or its
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